Loading...
To compare the effects of transdermal and oral estrogen therapy on risk for cardiovascular events, investigators used an administrative insurance database in an industry-funded retrospective 10-year study of outcomes in 5102 women (mean age, 55) who initiated either form of hormone therapy. Exclusion criteria included prior venous thromboembolism (VTE) or coronary heart disease (CHD) or filling a prescription for any progestin, estrogen injection, gel, or spray, or a contraceptive pill during the study period or the 180 days prior to filling the initial prescription for the transdermal or oral estrogen.
Users of transdermal and oral estrogen were exposed to a mean of 471 and 524 days of hormone treatment, respectively. Among transdermal and …